BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 17, 2004
View Archived Issues
More Development 'Unlikely' After Neurogen's RA Drug Phase II Miss
Another round of disappointing data for NGD 2000-1 caused Neurogen Corp.'s stock to drop nearly 19 percent Wednesday, and made further development of the product in rheumatoid arthritis an unlikely plan. (BioWorld Today)
Read More
Metabasis Prices IPO: $35M Helps Liver Product Pipeline
Read More
Santarus Gets FDA Approval For Rapinex Powder Version
Read More
Advanced Magnetics' Phase III Ferumoxytol Study Under Way
Read More
Axonyx Begins Second Pivotal Phenserine Trial In Alzheimer's
Read More
Other News To Note
Read More
Appointments And Advancements
Read More